These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 33205928)

  • 1. [Delayed effects of cerebrolysin in the prevention of cognitive impairment progression in the first degree relatives of patients with Alzheimer's disease: the role of the ApoE genotype].
    Selezneva ND; Gavrilova SI; Kolykhalov IV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(10. Vyp. 2):31-38. PubMed ID: 33205928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Citicoline in the treatment of cognitive impairment in first-degree relatives of AD patients: the influence of the ApoE genotype].
    Selezneva ND; Gavrilova SI; Roshchina IF; Ponomareva EV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(10. Vyp. 2):30-36. PubMed ID: 34870911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cerebrolysin Treatment Reduces the Risk of Mild Cognitive Decline to Dementia in 1st-Degree Relatives of Alzheimer's Patients: A Prospective Comparative Study].
    Selezneva ND; Gavrilova SI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(8):90-97. PubMed ID: 37655416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gender, apolipoprotein E genotype, and mesial temporal atrophy: 2-year follow-up in patients with stable mild cognitive impairment and with progression from mild cognitive impairment to Alzheimer's disease.
    Spampinato MV; Langdon BR; Patrick KE; Parker RO; Collins H; Pravata' E;
    Neuroradiology; 2016 Nov; 58(11):1143-1151. PubMed ID: 27590747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE).
    Jessen F; Spottke A; Boecker H; Brosseron F; Buerger K; Catak C; Fliessbach K; Franke C; Fuentes M; Heneka MT; Janowitz D; Kilimann I; Laske C; Menne F; Nestor P; Peters O; Priller J; Pross V; Ramirez A; Schneider A; Speck O; Spruth EJ; Teipel S; Vukovich R; Westerteicher C; Wiltfang J; Wolfsgruber S; Wagner M; Düzel E
    Alzheimers Res Ther; 2018 Feb; 10(1):15. PubMed ID: 29415768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prevention of progression of cognitive decline in the first-degree relatives of patients with Alzheimer's disease].
    Selezneva ND; Roshchina IF; Korovaitseva GI; Gavrilova SI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(10):30-36. PubMed ID: 30499493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [ApoE genotype and efficacy of neurotrophic and cholinergic therapy in Alzheimer's disease].
    Gavrilova SI; Kolykhalov IV; Korovaĭtseva GI; Zharikov GA; Kalyn IaB; Selezneva ND
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(4):27-34. PubMed ID: 15880838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The therapeutic potential of cerebrolysin in the preventive therapy of Alzheimer's disease].
    Gavrilova SI; Fedorova IaB; Kolykhalov IV; Odinak MM; Emelin AIu; Kashin AV; Selezneva ND; Kalyn IaB; Roshchina IF
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(8):24-8. PubMed ID: 18833104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein E genotypes and plasma levels in mild cognitive impairment conversion to Alzheimer's disease: A follow-up study.
    Scarabino D; Broggio E; Gambina G; Maida C; Gaudio MR; Corbo RM
    Am J Med Genet B Neuropsychiatr Genet; 2016 Dec; 171(8):1131-1138. PubMed ID: 27604972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apolipoprotein E genotype is not associated with cognitive impairment in older adults with bipolar disorder.
    Kerr DS; Stella F; Radanovic M; Aprahamian I; Bertollucci PH; Forlenza OV
    Bipolar Disord; 2016 Feb; 18(1):71-7. PubMed ID: 26877211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene-gene interactions among coding genes of iron-homeostasis proteins and APOE-alleles in cognitive impairment diseases.
    Tisato V; Zuliani G; Vigliano M; Longo G; Franchini E; Secchiero P; Zauli G; Paraboschi EM; Vikram Singh A; Serino ML; Ortolani B; Zurlo A; Bosi C; Greco A; Seripa D; Asselta R; Gemmati D
    PLoS One; 2018; 13(3):e0193867. PubMed ID: 29518107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of the APOE Genotype on Individual BrainAGE in Normal Aging, Mild Cognitive Impairment, and Alzheimer's Disease.
    Löwe LC; Gaser C; Franke K;
    PLoS One; 2016; 11(7):e0157514. PubMed ID: 27410431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease.
    Sala I; Illán-Gala I; Alcolea D; Sánchez-Saudinós MB; Salgado SA; Morenas-Rodríguez E; Subirana A; Videla L; Clarimón J; Carmona-Iragui M; Ribosa-Nogué R; Blesa R; Fortea J; Lleó A
    J Alzheimers Dis; 2017; 58(3):909-918. PubMed ID: 28527215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. APOE-dependent phenotypes in subjects with mild cognitive impairment converting to Alzheimer's disease.
    Morgen K; Frölich L; Tost H; Plichta MM; Kölsch H; Rakebrandt F; Rienhoff O; Jessen F; Peters O; Jahn H; Luckhaus C; Hüll M; Gertz HJ; Schröder J; Hampel H; Teipel SJ; Pantel J; Heuser I; Wiltfang J; Rüther E; Kornhuber J; Maier W; Meyer-Lindenberg A
    J Alzheimers Dis; 2013; 37(2):389-401. PubMed ID: 23948881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacological approaches to the therapy of Alzheimer's disease].
    Gavrilova SI
    Vestn Ross Akad Med Nauk; 2006; (9-10):30-4. PubMed ID: 17111921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of Apolipoprotein E Polymorphisms in Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Elderly: A Northern Greece Study.
    Tsolaki AC; Gatzima O; Daniilidou M; Lazarou E; Bamidis PD; Verykouki E; Iakovidou-Kritsi Z; Tsolaki M
    Neurodegener Dis; 2018; 18(4):216-224. PubMed ID: 30205398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Searching for Primary Predictors of Conversion from Mild Cognitive Impairment to Alzheimer's Disease: A Multivariate Follow-Up Study.
    López ME; Turrero A; Cuesta P; López-Sanz D; Bruña R; Marcos A; Gil P; Yus M; Barabash A; Cabranes JA; Maestú F; Fernández A
    J Alzheimers Dis; 2016 Mar; 52(1):133-43. PubMed ID: 27060953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment.
    Fleisher AS; Sun S; Taylor C; Ward CP; Gamst AC; Petersen RC; Jack CR; Aisen PS; Thal LJ
    Neurology; 2008 Jan; 70(3):191-9. PubMed ID: 18195264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. APOE, ACT and CHRNA7 genes in the conversion from amnestic mild cognitive impairment to Alzheimer's disease.
    Barabash A; Marcos A; Ancín I; Vázquez-Alvarez B; de Ugarte C; Gil P; Fernández C; Encinas M; López-Ibor JJ; Cabranes JA
    Neurobiol Aging; 2009 Aug; 30(8):1254-64. PubMed ID: 18078695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer's disease: 30 years of clinical use.
    Gavrilova SI; Alvarez A
    Med Res Rev; 2021 Sep; 41(5):2775-2803. PubMed ID: 32808294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.